Siri Helle1, Petter Andreas Ringen2, Ingrid Melle2, Tor-Ketil Larsen3, Rolf Gjestad4, Erik Johnsen5, Trine Vik Lagerberg2, Ole A Andreassen2, Rune Andreas Kroken5, Inge Joa6, Wenche Ten Velden Hegelstad7, Else-Marie Løberg8. 1. Division of Psychiatry, Haukeland University Hospital, Bergen, Norway. Electronic address: siri.helle@helse-bergen.no. 2. Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; NORMENT K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Norway. 3. Division of Psychiatry, Centre for Clinical Research in Psychosis, Stavanger University Hospital, Norway; Department of Clinical Medicine, University of Bergen, Norway. 4. Division of Psychiatry, Haukeland University Hospital, Bergen, Norway. 5. Division of Psychiatry, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Norway. 6. Division of Psychiatry, Centre for Clinical Research in Psychosis, Stavanger University Hospital, Norway; Network for Medical Sciences, Faculty of Social Sciences, University of Stavanger, Norway. 7. Division of Psychiatry, Centre for Clinical Research in Psychosis, Stavanger University Hospital, Norway. 8. Division of Psychiatry, Haukeland University Hospital, Bergen, Norway; Department of Clinical Psychology, University of Bergen, Norway.
Abstract
BACKGROUND: Patients with schizophrenia spectrum disorders and substance use may have an earlier onset of illness compared to those without substance use. Most previous studies have, however, too small samples to control for confounding variables and the effect of specific types of substances. The present study aimed to examine the relationship between substance use and age at onset, in addition to the influence of possible confounders and specific substances, in a large and heterogeneous multisite sample of patients with schizophrenia spectrum disorders. METHODS: The patients (N=1119) were recruited from catchment areas in Oslo, Stavanger and Bergen, Norway, diagnosed according to DSM-IV and screened for substance use history. Linear regression analysis was used to examine the relationship between substance use and age at onset of illness. RESULTS: Patients with substance use (n=627) had about 3years earlier age at onset (23.0years; SD 7.1) than the abstinent group (n=492; 25.9years; SD 9.7). Only cannabis use was statistically significantly related to earlier age at onset. Gender or family history of psychosis did not influence the results. CONCLUSION: Cannabis use is associated with 3years earlier onset of psychosis.
BACKGROUND:Patients with schizophrenia spectrum disorders and substance use may have an earlier onset of illness compared to those without substance use. Most previous studies have, however, too small samples to control for confounding variables and the effect of specific types of substances. The present study aimed to examine the relationship between substance use and age at onset, in addition to the influence of possible confounders and specific substances, in a large and heterogeneous multisite sample of patients with schizophrenia spectrum disorders. METHODS: The patients (N=1119) were recruited from catchment areas in Oslo, Stavanger and Bergen, Norway, diagnosed according to DSM-IV and screened for substance use history. Linear regression analysis was used to examine the relationship between substance use and age at onset of illness. RESULTS:Patients with substance use (n=627) had about 3years earlier age at onset (23.0years; SD 7.1) than the abstinent group (n=492; 25.9years; SD 9.7). Only cannabis use was statistically significantly related to earlier age at onset. Gender or family history of psychosis did not influence the results. CONCLUSION: Cannabis use is associated with 3years earlier onset of psychosis.
Authors: Else-Marie Løberg; Siri Helle; Merethe Nygård; Jan Øystein Berle; Rune A Kroken; Erik Johnsen Journal: Front Psychiatry Date: 2014-11-18 Impact factor: 4.157
Authors: Attila Szabo; Ibrahim A Akkouh; Thor Ueland; Trine Vik Lagerberg; Ingrid Dieset; Thomas Bjella; Pål Aukrust; Stephanie Le Hellard; Anne-Kristin Stavrum; Ingrid Melle; Ole A Andreassen; Srdjan Djurovic Journal: Front Psychiatry Date: 2020-07-02 Impact factor: 4.157
Authors: Priyanthi B Gjerde; Synne W Steen; Trude S J Vedal; Nils Eiel Steen; Elina J Reponen; Ole A Andreassen; Vidar M Steen; Ingrid Melle Journal: Front Psychiatry Date: 2022-03-29 Impact factor: 4.157
Authors: David M Weiss; Elizabeth Bernier; Douglas R Robbins; Katherine M Elacqua; Kelsey A Johnson; Kate Powers; Raquelle I Mesholam-Gately; Kristen A Woodberry Journal: Front Psychiatry Date: 2022-05-03 Impact factor: 4.157